BRIEF RESEARCH REPORT article
Front. Mol. Biosci.
Sec. Molecular Diagnostics and Therapeutics
Volume 12 - 2025 | doi: 10.3389/fmolb.2025.1556736
This article is part of the Research TopicCancer Biomarkers: Molecular Insights into Diagnosis, Prognosis, and Risk PredictionView all 15 articles
Clinical and Molecular Implications of cGAS/STING Signaling in Checkpoint Inhibitor Immunotherapy
Provisionally accepted
- 1Qilu Hospital, Shandong University, Jinan, China
- 2Department of Epidemiology, School of Public Health, Shandong University, Jinan, Shandong Province, China
- 3Department of Orthopedics, Shandong Provincial Hospital, Jinan, Shandong Province, China
- 4Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, jinan, China
- 5Shandong Provincial Hospital Affiliated to Shandong First Medical University, jinan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Recent studies reported that cytoplasmic dsDNA induced activation of cGAS/STING signaling has tremendous potential for antitumor immunity by inducing the production of type I IFN and resulting in activation of both innate and adaptive immunity. However, the potential role of STING signaling in modulating immunological checkpoint inhibitors (CPI) therapeutic efficacy remains unexplored. In this research, we employed the single-sample GSEA (ssGSEA) algorithm to calculate the enrichment score of STING signaling across fifteen immunotherapy cohorts, including melanoma, lung, stomach, urothelial, and renal cancer. Logistic and Cox regression models were utilized to investigate the association between STING signaling and CPI therapeutic response. Furthermore, we evaluated the tumor immunogenicity of STING1 molecule expression in TCGA pan-cancer datasets. The STING signaling was associated with improved immune response in
Keywords: cGAS/STING, checkpoint inhibitors therapy, tumor immunogenomic, predictive marker, CPI
Received: 07 Jan 2025; Accepted: 22 Apr 2025.
Copyright: © 2025 Chen, Zhong, Feng, Zhu, Xu, Kuang and Chong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Hao Chen, Qilu Hospital, Shandong University, Jinan, China
Mingjie Kuang, Department of Orthopedics, Shandong Provincial Hospital, Jinan, 250021, Shandong Province, China
Wei Chong, Shandong Provincial Hospital Affiliated to Shandong First Medical University, jinan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.